Interview: Sue Paish, CEO, LifeLabs, Canada
Sue Paish, Lifelabs’ Chief Executive Officer discusses the company’s recent purchase of BC Biomedical, why the market in BC and Ontario are so attractive, and the motivation behind LifeLabs’ collaboration…
LifeLabs provides laboratory testing services, which help physicians and other healthcare providers in the prevention, diagnosis, treatment and monitoring of disease and illness in patients.
Each year, LifeLabs provides more than 50 million laboratory tests to over 10 million patients and nearly 20,000 physicians in Canada.
Their tests help to:
LifeLabs also provides access to specialized clinical tests used to detect cancer, monitor heart disease, identify neurological disorders, and pinpoint individual allergies, among other things.
The company’s more than 3000 professionally-trained staff, conveniently-located Patient Service Centres and extensive network of couriers and mobile phlebotomists enable them to deliver care at home, in the community and across Canada.
At every step in the testing process, from collection to reporting, the goal is to deliver caring, compassionate, quality service that contributes to enhanced patient care.
Sue Paish, Lifelabs’ Chief Executive Officer discusses the company’s recent purchase of BC Biomedical, why the market in BC and Ontario are so attractive, and the motivation behind LifeLabs’ collaboration…
Dr David Reddy, Director General, IFPMA, and Dr Bettina Hamelin, President, IMC, jointly advocate for health innovation at the 2025 G7 Summit in Kananaskis (15-17 June). They call G7 leaders…
The biggest stories coming out of Canadian pharma and healthcare, including AstraZeneca’s acquistion of Canadian biotech Fusion Pharmaceuticals; Valeo Pharma’s new senior executive and board of directors, and generics maker…
Drs Neil Cashman and Larry Altstiel of ProMIS Neurosciences weigh in on recent progress towards an effective therapy for Alzheimer’s disease, potentially representing a break from three decades of scientific…
Some of the top stories coming out of Canadian healthcare and life sciences, including a new GSK flu vaccine deal, Amylyx Pharmaceuticals’ first approval for an ALS drug, and the…
In April, the Canadian Ministry of Health announced the government would not be proceeding with certain proposed amendments to the Patented Medicines Regulations which govern the Patented Medicine Prices Review…
In conversation in the October edition of DIA’s Global Forum magazine, Canadian Agency for Drugs and Technologies in Health (CADTH) CEO Suzanne McGurn highlights how the work of HTA bodies…
Writing in the September edition of DIA’s Global Forum magazine, Dr Judith Glennie examines the specific steps that have been taken in the journey towards a National Pharmacare program in…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health Canada’s consultation with Canadians on what a national strategy for high-cost rare disease…
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its current legal status, provincial variations in patient registrations, financial performance, the impact…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs, Canada has been struggling with the concept of ‘national pharmacare’ for…
The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt end to Canada’s participation in CanSino Biologics’ clinical trials the country’s first medical cannabis…
Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory body to reconsider their implementation. Companies cite the push for cost-effectiveness as a reason for…
See our Cookie Privacy Policy Here
